Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomised, controlled trial to compare allergic outcomes in children following vaccination with acellular pertussis antigen given at 2 months of age versus whole cell pertussis in the infant vaccine schedule

Next Previous
X
Search
Trial Profile

A double-blind, randomised, controlled trial to compare allergic outcomes in children following vaccination with acellular pertussis antigen given at 2 months of age versus whole cell pertussis in the infant vaccine schedule

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTP-hepatitis B vaccine (Primary) ; DTaP poliovirus vaccine; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Hib-DTaP-hepatitis B-poliovirus vaccine
  • Indications Pertussis
  • Focus Adverse reactions
  • Acronyms OPTIMUM

    • Most Recent Events

    • 07 Feb 2022 Results published in the Trials
    • 12 Feb 2021 Time frame changed from 18 months of age to 12 months of age. Planned number of patients increased. Additional clarification of Infanrix Hexa as acellular has been provided.
    • 12 Feb 2021 Planned number of patients changed from 150 to 3000.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top